Abstract: A method for preparing a sustained release formulation utilizing collagen and/or gelatin as a carrier, which comprises the steps:(i) preparing a uniform and high concentrated mixture with respect to the collagen and/or gelatin by blending an active ingredient, said collagen and/or gelatin, and water or an admixture consisting of water and a hydrophilic organic solvent under one of the conditions selected from:(A) the pH of the mixture is kept below 5 and the salt concentration of the mixture is retained below fiber-forming concentration;(B) chemically modified collagen and/or gelatin is employed; and(C) glucose is added to the mixture;(ii) molding the resultant mixture; and(iii) gradually eliminating the solvent from the molded product.
Abstract: A novel 2-pyridylthiazolidin-4-one derivative represented by the general formula ##STR1## wherein Ar denotes an aryl group unsubstituted or substituted with a halogen atom or with a lower alkoxy group; X denotes a straight-chain or branched-chain lower alkylene group or a single bond; R denotes a hydrogen atom, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, acyloxy, di(lower alkyl) amino, hydroxyl or aryl group, or denotes an aryl group substituted with a lower alkoxy group; and Py denotes a pyridyl group, and the acid addition salt thereof, which have an excellent platelet activating factor antagonsm.
Type:
Grant
Filed:
July 17, 1987
Date of Patent:
July 18, 1989
Assignees:
Sumitomo Pharmaceuticals Company, Limited, Sumitomo Chemical Company, Limited
Abstract: A process for the manufacture of a polypeptide (I) having the formula: ##STR1## which comprises steps of: (a) coupling, successively and in the order of the sequence of the polypeptide (I), the four protected fragments A, B, C and D or five protected fragments A, B, C, E and F,said fragment A by the formula, Leu-Gin-Asp-Ile-Met-Ser-Arg-NH.sub.2said fragment B by the formula, Gln-Leu-Ser-Ala-Arg-Lys-Leusaid fragment C by the formula, Arg-Lys-Val-Leu-Glysaid fragment D by the formula, Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyrsaid fragment E by the formula, Ile-Phe-Thr-Asn-Ser-Tyrand said fragment F by the formula, Tyr-Ala-Asp-Ala being represented, respectively, and(b) eliminating, at the end of sequence, all the protecting groups to provide the polypeptide (I) which is active on the stimulation of the release of the growth hormone and thus is very useful as medicine for treatment of growth hormone deficiency disease and the like.
Abstract: A novel antibiotic of the formula: ##STR1## wherein R is a hydrogen atom or a methyl group and preparation of the antibiotic by cultivating Nocardia sp. SC-4710.
Type:
Grant
Filed:
December 19, 1986
Date of Patent:
August 16, 1988
Assignees:
Sumitomo Chemical Company, Sumitomo Pharmaceuticals Company, Limited
Abstract: A cephem derivative represented by the general formula ##STR1## wherein R.sup.1 represents hydrogen or methyl, R.sup.2 represents carboxyl or esterified carboxyl, and n represents 0 or 1, or a pharmaceutically acceptable salt thereof; intermediates for the cephem derivative or salt thereof; processes for producing these compounds; and a pharmaceutical composition and method for preventing or treating bacterial infectious diseases, wherein the cephem derivative or the salt thereof is used.
Abstract: A compound of the formula: ##STR1## wherein A is a carbonyl group or a sulfonyl group;B is either one of the formulas: ##STR2## (in which E is a methylene group, an ethylene group or an oxygen atom and a full line accompanying a broken line ( ) indicates a single bond or a double bond), ##STR3## (in which F is a methylene group or an ethylene group and a full line accompanying a broken line ( ) is as defined above) and ##STR4## (in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are each a hydrogen atom or a methyl group) when A represents a carbonyl group, or B is a 1,2-phenylene group when A represents a sulfonyl group;D is an ethylene group, an ethenylene group or an ethynylene group, of which one or more may be optionally substituted with hydroxyl; andn is an integer of 0, 1 or 2, or its acid addition salt. These compounds are useful for the treatment or psychosis.
Abstract: Novel .beta.-lactam compounds classified into penem compounds, a process for preparing the same and use of such .beta.-lactam compounds are disclosed. These .beta.-lactam compounds exhibit excellent antimicrobial activities useful as pharmaceuticals or they are important intermediates for the synthesis of compounds having antimicrobial activities.
Abstract: A compound of the formula ##STR1## wherein T.sub.1 is lower alkylene, lower alkenylene or a single bond; X is ##STR2## T.sub.2 is carbonyl, lower alkylene or a single bond; R.sub.2 is phenyl, phenoxy, pyridyl, pyrimidinyl, furyl, thienyl, lower cycloalkyl or adamantyl;R.sub.2 and R.sub.6, when taken together with the nitrogen to which they are attached form pyrrolidinyl, piperidinyl or azacyclooctanyl;R.sub.14 is COOR.sub.8 or --R.sub.3 R.sub.9 wherein T.sub.3 is lower alkylene and R.sub.9 is lower alkoxy, lower cycloalkyl, cyano, polyfluoro-lower alkyl or pyridyl; andR.sub.1 and R.sub.5 are each lower alkyl or lower alkenyl, useful in the treatment of cardiovascular diseases.
Abstract: A cephem compound represent by the general formula ##STR1## wherein, R.sup.1 represents hydrogen or lower alkyl, R.sup.2 and R.sup.3 are the same or different and each represents hydrogen or lower alkyl, R.sup.4 represents carboxyl or esterified carboxyl, and n represents 0 or 1, a salt of the cephem compound, and a process for producing the cephem compound or a salt thereof. Compounds of the above formula and salts thereof are valuable as antibacterial agents and are especially useful as oral drugs in the prevention or treatment of bacterial infectious diseases.
Abstract: A therapeutic drug for dementia is provided which comprises, as an active ingredient, DL- or L-threo-3,4-dihydroxyphenylserine of the formula ##STR1## or its salt.
Abstract: Diuretics containing an efficient amount of L- or DL-threo-3-(3,4-dihydroxyphenyl)-serine or a pharmaceutical acceptable salt thereof are applied orally or parenterally. They are effected particularly to anasarca patients. They will also be effective to myxedema, Addison's disease and other ADH-excessive syndrome patients. They are applied in the form of tablet, capsules, syrup, suspension or liquid.